Detalhe da pesquisa
1.
Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes.
Pharm Dev Technol
; 29(1): 52-61, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38230653
2.
Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.
Mol Pharm
; 20(6): 2864-2875, 2023 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37134184
3.
Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer.
Molecules
; 28(7)2023 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37049910
4.
Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.
J Nanobiotechnology
; 19(1): 138, 2021 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33985511
5.
Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
Mol Pharm
; 14(2): 502-512, 2017 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28029256
6.
Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
J Control Release
; 360: 858-871, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37473808
7.
Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.
J Pharm Sci
; 111(2): 450-457, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34547305
8.
Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.
Int J Pharm
; 586: 119541, 2020 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544521
9.
Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
Int J Pharm
; 499(1-2): 195-204, 2016 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26752086